TABLE 3.

SCIg and IVIg Features

Feature	SCIg	IVIg
Pharmacokinetics	Stable serum trough IgG level	Variability in serum IgG level between peak and trough
Efficacy	Clinical efficacy demonstrated in PIDD (noninferior when compared to IVIg)	Clinical efficacy demonstrated in PIDD and other autoimmune disorders
Systemic side effects	Infrequent	Frequent
Local site reactions	Common	Infrequent
Administration	Self administration; patient autonomy	Infusion center/home setting with nursing support for venous access
Average length of infusion	1–2 hours	2–4 hours
Dosing interval	Weekly	Variable – every 2 to 4 weeks
Most common adverse events	Local reactions, headache, vomiting, and pain	Headache, chills, fever, myalgias, fatigue, nausea
Premedication	N/A	Acetaminophen, steroids, antihistamines (oral or IV) as needed
Patient satisfaction	Flexibility of infusion frequency, site, patient autonomy, increased flexibility and independence	Need for venous access, desire for administration in an out-patient setting, need for nursing support staff
Associated costs	Cost of immunoglobulin, self-administration supply costs	Cost of immunoglobulin, nursing and facility costs, equipment costs, related infusion costs (i.e., premedication, hydration)

Sources: Adapted from Blaese 2007, Hizentra™ Prescribing Information 2010, Skoda-Smith 2010.